DnaNudge raises £43.6m in Series A funding led by Ventura Capital to scale rapid genetic testing
The investment round was led by Ventura Capital and will accelerate international deployment of the company's diagnostic platform.
DnaNudge develops consumer genetics testing and medical diagnostics technology that combines DNA profiling with lifestyle factors. Its portable platform delivers rapid PCR testing for infectious diseases and personalised nutrition guidance.
London-based genetics testing pioneer DnaNudge has secured £43.6m in a Series A funding round led by Ventura Capital, with participation from Bank Julius Baer. The fresh capital will be directed towards scaling the international deployment of the company's rapid genetic testing solutions, which include its lab-free RT-PCR COVID-19 test.
Originally launched to provide personalised nutrition shopping guidance based on consumer DNA, DnaNudge adapted its technology to deliver clinical-grade infectious disease screening without the need for traditional laboratory infrastructure. The platform has seen significant adoption across healthcare providers and cultural institutions, while also laying groundwork for upcoming consumer skincare applications.
From the founder
"The game-changing nature of our innovation has created an extraordinary commercial opportunity within next-generation medical diagnostics, and the global investor community is very excited by the transformative potential of a rapid, gold-standard RT-PCR testing platform that can screen for multiple viruses simultaneously. We are delighted to have completed this successful fund-raise which will allow us to dramatically speed our plans for worldwide availability, particularly in the US, Japan, Europe, and other key territories where interest is extremely high."
Chris Toumazou
CEO and co-founder at DnaNudge
Investor perspective
"We methodologically reviewed the world’s most promising breakthrough innovations in commercialised disease testing technology and set our sole focus on DnaNudge. The gold-standard RT-PCR platform brought to market by DnaNudge is a quantum leap in terms of PCR testing time, cost and ease. With the ability to quickly add screening for multiple emerging disease variants on the same testing panel, the clinical applications for this technology are exponential. What Professor Toumazou and the DnaNudge team have achieved is historic in terms of their contribution to not only COVID-19 rapid testing but more importantly their multi virus testing products. Powered by this investment, DnaNudge is well-positioned to become the new standard for disease testing globally."
Mo El Husseiny
Founder and Managing Partner, Ventura Capital
Use of funds
- 01Expand into international markets
